

# Asthma Treatments Referral Form

PATIENT INFORMATION (Complete or fax existing chart)	PRESCRIBER INFORMATION
Patient Name: _____ Address: _____ City, State, Zip: _____ Phone: _____ 2 <sup>nd</sup> Phone: _____ _____ DOB: _____ Gender: M F Last 4 S.S: _____ Weight: Ht: Allergies:	Prescriber Name: _____ State License: _____ NPI #: _____ DEA: _____ Phone: _____ Address: _____ Fax: _____ City, State, Zip: _____ Contact Person: _____ Phone: _____

INSURANCE INFORMATION - INSTEAD - just send us a copy of the patients prescription / insurance cards (front & back)	
Primary Insurance: _____ City, State, Zip: _____ Plan #: _____ Group #: _____ Phone: _____	RX Card (PBM): _____ BIN: _____ PCN: _____ City, State, Zip: _____ Group #: _____ Phone: _____

DIAGNOSIS /CLINICAL INFORMATION	
<input type="checkbox"/> J45.40 Moderate Persistent Asthma, Uncomplicated <input type="checkbox"/> J45.50 Severe persistent asthma, uncomplicated <input type="checkbox"/> J45.51 Severe persistent asthma with (acute) exacerbation Eosinophil Count: _____ cells/ $\mu$ L Date of Test: _____	<input type="checkbox"/> M30.1 Polyarteritis with lung involvement [Churg-Strauss] <input type="checkbox"/> J33.9 Nasal Polyps, Unspecified <input type="checkbox"/> J33.0 Polyp of Nasal Cavity <input type="checkbox"/> L50.1 Idiopathic urticaria <input type="checkbox"/> Other: _____
Needs by Date: _____ Ship to: Patient Office Other: _____	
Lab Orders: _____	

Fasenra	
<input type="checkbox"/> FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe (administered by healthcare professional) <input type="checkbox"/> FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector (Self administered)	<input type="checkbox"/> Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses QTY: ___ Refills: ___ <input type="checkbox"/> Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks – QTY: ___ Refills: ___

Nucala
<input type="checkbox"/> Prefilled syringe <input type="checkbox"/> Vial <input type="checkbox"/> Pen <input type="checkbox"/> Inject 100 mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 300 mg (3 separate 100 mg injections) subcutaneously once every 4 weeks <input type="checkbox"/> Inject _____ mg ( _____ separate 100 mg injections) subcutaneously once every _____ weeks

Dupixent Pre-filled syringe, package of 2	
<input type="checkbox"/> Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1 Subsequent (maintenance) dose: 200 mg SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15 Other: Initial: _____ Subsequent: Dose _____ Frequency _____ QTY: _____ pk (2 syringes) Refills _____	<input type="checkbox"/> Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1 Subsequent (maintenance) dose: 300 mg SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Xolair
<input type="checkbox"/> Prefilled syringe <input type="checkbox"/> Vial Prescription Type: <input type="checkbox"/> New start <input type="checkbox"/> Restart <input type="checkbox"/> Continued Tx SIG <input type="checkbox"/> 75 mg/dose every 4 weeks      SIG <input type="checkbox"/> 150 mg/dose every 4 weeks      Last injection date: _____ SIG <input type="checkbox"/> 300 mg/dose every 4 weeks      SIG <input type="checkbox"/> 225 mg/dose every 2 weeks      SIG <input type="checkbox"/> 225 mg/dose every 4 weeks SIG <input type="checkbox"/> 375 mg/dose every 2 weeks      SIG <input type="checkbox"/> 300 mg/dose every 2 weeks

SIGNATURE
We hereby authorize Biotek Remedys to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral
X _____ Date: _____ Product Substitution Permitted